Liraglutide and empagliflozin reduce diabetic heart damage through complementary antioxidant and anti-inflammatory pathways | Research

The takeaway

Liraglutide (GLP-1RA) and empagliflozin (SGLT2i) alleviate diabetic cardiomyopathy through distinct but complementary mechanisms: both reduce oxidative stress and inflammation, supporting combination therapy for cardiac protection in diabetes.

Complementary cardiac protection
Liraglutide and empagliflozin protect the diabetic heart through distinct antioxidant and anti-inflammatory pathways—mechanistic support for combination therapy

What the researchers found

Liraglutide + empagliflozin: both ↓oxidative stress and ↓inflammation in DCM. Distinct but complementary mechanisms. Supports combination therapy rationale.

Why it matters

Understanding the complementary mechanisms of these two drug classes explains clinical trial findings and supports rational combination prescribing for diabetic heart protection.

How the study worked

Diabetic cardiomyopathy study; liraglutide vs empagliflozin vs combination; oxidative stress and inflammation markers.

What this study cannot tell us

Preclinical study. Specific oxidative/inflammatory markers not detailed in abstract preview. Combination effects may differ in human hearts.

How to read the evidence

Preclinical mechanistic study.

When this study was published

Published in 2025.

The bigger picture

This adds mechanistic depth to the clinical evidence for SGLT2i + GLP-1RA combination therapy, confirming they protect the heart through different but complementary pathways.

Questions still open

Does the combination provide additive or synergistic cardiac protection?
Which oxidative stress pathway is unique to each drug?
Should all diabetic heart failure patients receive both drug classes?

Common questions

Why take both an SGLT2 inhibitor and a GLP-1 drug for heart protection?

This study shows they protect the heart through different mechanisms: both reduce harmful oxidative stress and inflammation, but through complementary pathways. Using both provides broader coverage against the multiple damaging processes that harm the diabetic heart.

Is this different from their blood sugar effects?

Yes—this is about direct heart protection, independent of glucose control. Both drugs reduce oxidative damage and inflammation in heart muscle cells through their own distinct mechanisms, explaining why combination therapy provides better cardiovascular outcomes in clinical trials.

Read the original research

Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.

Gaceta medica de Mexico

View on PubMed ↗Publisher’s paper ↗

Citation

Uçar-Ekin, Cemre; Oflazoğllu-Diken, Huda; Baksi, Nazan; Aşir, Fırat; Şahika-Gökdemir, Gül. (2025). Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.. Gaceta medica de Mexico. https://doi.org/10.24875/GMM.25000112